Cargando…
Humoral Immune Response of SARS‐CoV‐2–Infected Patients with Cancer: Influencing Factors and Mechanisms
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)–infected patients with cancer show worse outcomes compared with patients without cancer. The humoral immune response (HIR) of patients with cancer against SARS‐CoV‐2 is not well characterized. To better understand it, we conduc...
Autores principales: | Esperança‐Martins, Miguel, Gonçalves, Lisa, Soares‐Pinho, Inês, Gomes, Andreia, Serrano, Marta, Blankenhaus, Birte, Figueiredo‐Campos, Patrícia, Catarina‐Marques, Ana, Castro‐Barbosa, Ana, Cardoso, Ana, Antunes‐Meireles, Pedro, Atalaia‐Barbacena, Henrique, Gaspar, Pedro, Howell‐Monteiro, Patrícia, Pais‐de‐Lacerda, António, Mota, Catarina, Veldhoen, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242329/ https://www.ncbi.nlm.nih.gov/pubmed/34018280 http://dx.doi.org/10.1002/onco.13828 |
Ejemplares similares
-
The Effect of Chronic and Inhospital Exposure to Renin-Angiotensin System Inhibitors on the Outcome and Inflammatory State of Coronavirus Disease 2019 Adult Inpatients
por: Gaspar, Pedro, et al.
Publicado: (2021) -
Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
por: Chang, Elaine, et al.
Publicado: (2021) -
Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China
por: Fang, Wenfeng, et al.
Publicado: (2019) -
Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non‐Small Cell Lung Cancer
por: Akamatsu, Hiroaki, et al.
Publicado: (2019) -
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy
por: Bilen, Mehmet Asim, et al.
Publicado: (2019)